In this warm, informative podcast, our very own Dr Duncan Still is interviewed by Prof David Nutt of DrugScience (and many other ventures). Duncan talks about his own journey into medicine and particularly his passion for teaching more integrative approaches to health & healing.

Participants who reported lifetime co-use of cannabis and psychedelics (N = 63) were asked open-ended questions about their most recent simultaneous co-use experience.

PAP offers a promising avenue for a deeper understanding and therapeutic resolution of traumatic dissociation, which could fundamentally improve the treatment paradigm for many trauma-related disorders.

In this essay, we aim to explore the benefits and risks of integration groups, and offer a preliminary set of guidelines to physicians, researchers and individuals to help assess and evaluate these groups

Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. In this rapid review, we aimed to evaluate the strength of evidence for a placebo explanation of the reported effects of microdosing.

This newsy article links to 7 recent psilocybin studies on alcohol use disorder, anorexia, long Covid, learning, brain connectivity, auditory perception and cluster headaches.

Searches for microdosing in the US remained stable until 2014, then increased annually thereafter, with a cumulative increase by a factor of 13.4 from 2015 to 2023 (7.9 per 10 million to 105.6 per 10 million searches, respectively). In 2023, there were 3.0 million microdosing searches in the US.

How much of this sometimes life-altering experience is chemical and empirical, and how much is mental and subjective?

Within the class of drugs generally classified as psychedelics, psilocybin has the highest past-year and past-month prevalence rates among U.S. adults. Of those ages 18 and older, 3.1 percent — or approximately 8 million people — used psilocybin in 2023.

The Dutch government should allow treatment with ecstasy chemical MDMA for people with post-traumatic stress disorder (PTSD), an advisory body set up to look at the issue has recommended.

Even after selecting patients who initially responded to ketamine, 59.5 percent of the enriched participants still dropped out of the trial before its completion, largely due to a lack of efficacy.

Can the acute subjective effects of classic psychedelics be dissociated from their sustained therapeutic properties? Several plausible clinical scenarios are proposed to offer clarity on and potentially answer this question.

A global reference on drug markets, trends and policy developments, the World Drug Report offers a wealth of data and analysis and in 2024 comprises several elements tailored to different audiences.

Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration.

Psychedelic Alpha issued a helpful discussion of both the Institute for Clinical & Economic Review's Final Evidence Report and Lykos Therapeutic's response.

Legions of brands are putting 4-AcO-DMT in products, but the drug’s widespread availability has some experts worried.

The intensity of the SDI ratings was associated with plasma 5-MeO-DMT concentrations. MEQ-30 and EDI scores generally increased with the BPL-003 dose; 60% of participants had a ‘complete mystical experience’ at 10 and 12 mg doses.

While both MDMA and serotonergic psychedelics produce prosocial effects, they differ in the mechanisms through which they do this. These differences affect the types of psychosocial interventions that may work best with each compound.

Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs.

Conclusions At-home, telehealth-supported ketamine administration was largely safe, well-tolerated, and associated with improvement in patients with depression. Strategies for combining psychedelic-oriented therapies with rigorous telehealth models, as explored here, may uniquely address barriers to mental health treatment.